heparin vs oritavancin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of heparin and oritavancin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
In addition, oritavancin does not affect tests that are used for diagnosis of Heparin Induced Thrombocytopenia (HIT).
Heparin Sodium
Orbactiv
Heparin is a medicine that helps prevent and treat blood clots. It is given as an injection into a vein or under the skin.
KIMYRSA is an antibiotic medicine. It is used to treat serious skin infections caused by certain bacteria.
Heparin is used to prevent and treat blood clots in your veins and lungs. It can also prevent clots after surgery or if you have an irregular heartbeat called atrial fibrillation. Heparin can also treat blood clotting problems throughout your body and prevent clots during surgery, blood transfusions, or dialysis.
KIMYRSA treats acute bacterial skin and skin structure infections (ABSSSI) in adults. These infections are caused by specific Gram-positive bacteria. KIMYRSA can fight Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, among others. Your doctor will determine if KIMYRSA is the right medicine for your infection.
Heparin works by stopping certain proteins in your blood from forming clots. It helps to thin your blood and prevent new clots from forming. It does not dissolve existing blood clots, but it can keep them from getting bigger.
KIMYRSA is a lipoglycopeptide antibiotic. It works by stopping bacteria from building their cell walls. This kills the bacteria and helps to clear the infection.
- • Bleeding
- • Irritation at the injection site
- • Allergic reactions
- • Increased liver enzyme levels
- • Headache
- • Nausea
- • Vomiting
- • Abscesses on limbs or under the skin
- • Diarrhea
- Heparin-Induced Thrombocytopenia 1,207
- Nausea 708
- Drug Hypersensitivity 603
- Vomiting 572
- Hypotension 547
- Pruritus 162
- Urticaria 105
- Rash 84
- Chills 83
- Back Pain 81
Heparin can cause serious bleeding, which can be fatal. It can also cause a severe reaction called heparin-induced thrombocytopenia (HIT), where your body attacks your own platelets. Make sure your doctor knows if you have ever had HIT. Using the wrong strength of heparin can also cause fatal bleeding.
You should not take KIMYRSA if you are using intravenous heparin. Do not use heparin for 5 days (120 hours) after getting KIMYRSA. Serious allergic reactions, including anaphylaxis, have been reported. Tell your doctor right away if you have signs of an allergic reaction.
If you are pregnant, talk to your doctor about the risks and benefits of using heparin. Preservative-free heparin is recommended during pregnancy if available. It is not known if heparin passes into breast milk, so it is recommended to avoid breastfeeding while using this medicine.
It is not known if KIMYRSA can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if KIMYRSA passes into breast milk. Talk to your doctor about the best way to feed your baby if you take KIMYRSA.
Also Compare, Nearby Drugs
Compare oritavancin with
How to Read This heparin vs oritavancin Comparison
heparin is classified in the Unfractionated Heparin drug class, while oritavancin sits within the Lipoglycopeptide Antibiotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, heparin has 3,637 submissions while oritavancin has 515. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to oritavancin does not interfere with the blood tests used to find a specific type of heparin allergy.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for heparin or oritavancin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.